Skip to content
Open access

Rationale and design of the EXCELSIOR-CKD trial: intensive blood pressure and lipid control in advanced chronic kidney disease.

Aug 2026 · Kidney Research and Clinical Practice · 0 citations · 42 references
Medicine

TL;DR

As the first randomized trial to determine whether intensive SBP and LDL-C lowering improve kidney outcomes in advanced CKD, this study could help define optimal targets and inform future guideline recommendations.

Abstract

Background Although blood pressure and lipid control are key in advanced chronic kidney disease (CKD), the optimal targets for systolic blood pressure (SBP) and low-density lipoprotein cholesterol (LDL-C) remain unclear because patients with estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m2 were often excluded or underrepresented in prior trials. This study aims to compare the clinical outcomes of intensive versus standard control strategies for SBP and LDL-C in patients with advanced CKD. Methods This multicenter, open-label, randomized controlled trial with a 2 × 2 factorial design is being conducted across 13 centers in Korea. Adults aged ≥19 years with eGFR ≥15 and <45 mL/min/1.73 m2 , SBP ≥130 mmHg, and LDL-C ≥100 mg/dL are eligible. Participants will be randomized according to intensive or standard targets for SBP (<120 mmHg vs. <140 mmHg) and LDL-C (<70 mg/dL vs. <100 mg/dL). The effects of blood pressure and lipid interventions will be evaluated independently, sharing the same primary endpoint: time to the first composite kidney outcome, including ≥40% sustained decline in eGFR, initiation of kidney replacement therapy, sustained eGFR <10 mL/min/1.73 m2 , or kidney death. Secondary endpoints will include eGFR slope and major adverse cardiovascular events. Participants will be followed up for 3 years, with an additional 3 years for the observational phase. Results This report describes the rationale and design; trial results are pending. Conclusion As the first randomized trial to determine whether intensive SBP and LDL-C lowering improve kidney outcomes in advanced CKD, this study could help define optimal targets and inform future guideline recommendations.

Read PDF

Similar papers

Open access Aug 2026

Achieved systolic blood pressure and cardiovascular outcomes in advanced chronic kidney disease

In nephrology-referred patients with advanced CKD, achieved SBP around 120–<130 mmHg (near 125 mmHg) was associated with the lowest cardiovascular and mortality risk, while SBP ≥140 mmHg, especially ≥160 mmHg, was consistently associated with higher MACE risk.

Ehab Al-sodany, K. Szummer, Joakim Österman et al. · 0 citations
Open access Aug 2026

Blood Pressure, Kidney Function, and Kidney Mortality Among Mexican Adults.

Elevated BP as a major modifiable risk factor for kidney failure mortality, CKD, and albuminuria is highlighted in this large prospective study in Mexican adults.

Doreen Zhu, P. Kuri-Morales, Rachel Wade et al. · 0 citations
Review Open access Sep 2026

Effects of Wuqinxi on blood pressure and lipids in hypertensive middle-aged and elderly adults: a meta-analysis

Purpose This study aimed to quantify the therapeutic effects of standardized Wuqinxi exercise on blood pressure, lipid profile, and resting heart rate in middle-aged and older adults with primary hypertension, and to grade the evidence certainty using the GRADE framework. Methods We systematically searched Web of Scien...

Tian-Hao Zhang, Ming Guo, Tao Li et al. · 0 citations
Open access Sep 2026

Salt Intake and Kidney Outcomes in Older Adults With Chronic Kidney Disease: A Stage‐Specific Cohort Study

Excessive salt intake was associated with adverse kidney outcomes in CKD Stage 3 but not in Stages 4–5, and results suggest that salt restriction may be most beneficial in the early stages of CKD in this population.

Hiroaki Miyauchi, Tatsuhiko Azegami, Takashin Nakayama et al. · 0 citations
Open access Sep 2026

Historical Gaps in Kidney and Cardiovascular Risk Assessment Among Patients with Diabetes and Hypertension: A Real-World Primary Care Study.

UACR testing was underutilized among patients with diabetes and hypertension, and consistent screening could have identified individuals who would benefit from guideline directed antiproteinuric therapies.

Jian Roushani, Sachin V. Pasricha, L. Dubrofsky et al. · 0 citations
Open access Sep 2026

Blood pressure and cardiovascular risk in adults with non-proteinuric chronic kidney disease without diabetes.

A U-shaped association observed among individuals receiving antihypertensive treatment suggests that the relationship between BP and cardiovascular risk may be complex in this population, highlighting the potential importance of individualized clinical assessment.

Yuta Suzuki, Masachika Nishikawa, Hidehiro Kaneko et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.